齐拉西酮治疗首发精神分裂症的临床疗效及安全性分析

Effect and safety of ziprasidone on first episode schizophrenia

目的探讨齐拉西酮与利培酮治疗首发精神分裂症的临床疗效及安全性。方法将128例首发精神病患者随机分为2组,利培酮组(62例)给予利培酮口服,齐拉西酮组(66例)给予齐拉西酮口服。比较两组阳性与阴性症状量表(PANSS)评分的改变及不良反应发生率。结果齐拉西酮组、利培酮组的治疗总有效率分别为97.0%和95.2%(P>0.05);治疗后4周、8周齐拉西酮组阴性症状评分显著低于利培酮组(P<0.05);利培酮组泌乳/月经异常、静坐不能及体重增加的发生率显著高于齐拉西酮组(P<0.05)。结论齐拉西酮与利培酮治疗首发精神分裂症患者疗效相当,但齐拉西酮可显著改善阴性症状,不良反应较少。

Objective To explore the clinical effect and safety of ziprasidone combined with risperidone on first episode schizophrenia. Methods 128 cases with fast episode schizophrenia were randomly divided into 2 groups. Control group（ n = 62 ） received risperidone, experience group （ n = 66 ） was given ziprasidone. Clinical effect, PANSS scores and incidence of adverse reactions of the two groups were compared. Results The effective rates of experience group and control group were 97.0% and 95.2% respectively （ P 〉 0.05 ） ; Negative scores of experience group at 4 and 8 weeks after treatment were much lower than those of control group （ P 〈 0. 05 ） ; The incidence of lactation and men- struation abnormality, akathisia, weight gain of control group were much higher than that of experience group （P 〈 0. 05 ）. Conclusion Both ziprasidone and risperidone have equivalent effect in treatment for first episode schizophreni- a, but ziprasidone can greatly improve the negative score with less adverse reactions.